Targeting innovative treatments for multiple sclerosis and other neuroinflammatory pathology Englewood Cliffs, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s…

Source

Previous articleMindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
Next articleRed Light Holland Receives Receipt for Final Short-form Prospectus for Previously Announced $10 Million Bought Deal Public Offering

RELATED ARTICLESMORE FROM AUTHOR